RxDoctor Payments Data

Addam Masri, MD

Family Medicine · Apopka, FLNPI 1851335327

Payments from drug & device makers

$7,065in general payments, 2019–2025

Across 336 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$926
  • Lilly USA, LLC$903
  • AstraZeneca$803
  • Novo Nordisk$763
  • Boehringer Ingelheim$630
  • AbbVie$514
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$6,93898%
  • Education$1122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,065 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$151,412
Medicare patients
127
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$72,699
OzempicSemaglutide36$49,297
MounjaroTirzepatide38$46,495
Xigduo XrDapaglifloz Propaned/Metformin35$27,537
FarxigaDapagliflozin Propanediol24$25,056
GlyxambiEmpagliflozin/Linagliptin20$19,514
Synjardy XrEmpagliflozin/Metformin Hcl12$18,961
TrulicityDulaglutide18$18,348
JardianceEmpagliflozin11$14,901
VyvanseLisdexamfetamine Dimesylate16$8,340
Liothyronine Sodium160$6,787
ProgesteroneProgesterone, Micronized111$5,938
Rosuvastatin Calcium334$3,803
Testosterone Cypionate66$3,281
SymbicortBudesonide/Formoterol Fumarate11$2,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$166$74,12875 claims
Lilly USA, LLCMounjaro, Trulicity$903$64,84356 claims
Boehringer IngelheimGlyxambi, Synjardy Xr, Jardiance$630$53,37643 claims
Novo NordiskOzempic$763$49,29736 claims
AstraZenecaFarxiga, Symbicort$803$27,65435 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$55$1,769271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Apopka

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →